MX2021008136A - Compuestos de quinolina como inhibidores de quinasas tam y met. - Google Patents
Compuestos de quinolina como inhibidores de quinasas tam y met.Info
- Publication number
- MX2021008136A MX2021008136A MX2021008136A MX2021008136A MX2021008136A MX 2021008136 A MX2021008136 A MX 2021008136A MX 2021008136 A MX2021008136 A MX 2021008136A MX 2021008136 A MX2021008136 A MX 2021008136A MX 2021008136 A MX2021008136 A MX 2021008136A
- Authority
- MX
- Mexico
- Prior art keywords
- tam
- inhibitors
- quinoline compounds
- met kinases
- met
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente, se proporcionan compuestos de la Fórmula I: (ver Fórmula) o sales de estos aceptables desde el punto de vista farmacéutico, en donde X1, X2, X3, R1, R2, R3, R4, R5, R6 y R7 son como se definen en la presente, que son inhibidores de una o más quinasas TAM y/o quinasa c-Met, y son útiles en el tratamiento y la prevención de enfermedades que se pueden tratar con un inhibidor de quinasa TAM y/o un inhibidor de quinasa c-Met.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962787965P | 2019-01-03 | 2019-01-03 | |
| US201962858819P | 2019-06-07 | 2019-06-07 | |
| US201962947720P | 2019-12-13 | 2019-12-13 | |
| PCT/IB2020/050009 WO2020141470A1 (en) | 2019-01-03 | 2020-01-02 | Quinoline compounds as inhibitors of tam and met kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008136A true MX2021008136A (es) | 2021-08-11 |
Family
ID=69185648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008136A MX2021008136A (es) | 2019-01-03 | 2020-01-02 | Compuestos de quinolina como inhibidores de quinasas tam y met. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200216416A1 (es) |
| EP (1) | EP3906234A1 (es) |
| JP (1) | JP2022515880A (es) |
| KR (1) | KR20210110664A (es) |
| CN (1) | CN113302188A (es) |
| AU (1) | AU2020205035A1 (es) |
| BR (1) | BR112021012956A2 (es) |
| CA (1) | CA3125559A1 (es) |
| CO (1) | CO2021008535A2 (es) |
| CR (1) | CR20210364A (es) |
| IL (1) | IL284570A (es) |
| MA (1) | MA54656A (es) |
| MX (1) | MX2021008136A (es) |
| SG (1) | SG11202106897XA (es) |
| TW (1) | TWI745824B (es) |
| UY (1) | UY38536A (es) |
| WO (1) | WO2020141470A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019323455A1 (en) * | 2018-08-24 | 2021-04-01 | Transthera Sciences (Nanjing), Inc. | Novel quinoline derivative inhibitor |
| CN112625026B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
| CN116783166A (zh) * | 2021-02-01 | 2023-09-19 | 江苏恒瑞医药股份有限公司 | 二甲酰胺类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007033196A1 (en) * | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CA2655128A1 (en) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
| JP5314050B2 (ja) * | 2008-01-23 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | ４−ピリジノン化合物および癌についてのその使用 |
| WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| US10208034B2 (en) * | 2014-12-25 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
| KR101829998B1 (ko) | 2015-11-04 | 2018-02-19 | 롬엔드하스전자재료코리아유한회사 | 착색 감광성 수지 조성물 및 이를 이용한 차광성 스페이서 |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019141202A1 (zh) * | 2018-01-17 | 2019-07-25 | 南京药捷安康生物科技有限公司 | Tam家族激酶/和csf1r激酶抑制剂及其用途 |
| CN112625026B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
-
2020
- 2020-01-02 UY UY0001038536A patent/UY38536A/es unknown
- 2020-01-02 BR BR112021012956-1A patent/BR112021012956A2/pt not_active Application Discontinuation
- 2020-01-02 JP JP2021538367A patent/JP2022515880A/ja active Pending
- 2020-01-02 CR CR20210364A patent/CR20210364A/es unknown
- 2020-01-02 MA MA054656A patent/MA54656A/fr unknown
- 2020-01-02 TW TW109100070A patent/TWI745824B/zh not_active IP Right Cessation
- 2020-01-02 US US16/732,733 patent/US20200216416A1/en not_active Abandoned
- 2020-01-02 KR KR1020217024137A patent/KR20210110664A/ko not_active Application Discontinuation
- 2020-01-02 CA CA3125559A patent/CA3125559A1/en not_active Abandoned
- 2020-01-02 MX MX2021008136A patent/MX2021008136A/es unknown
- 2020-01-02 WO PCT/IB2020/050009 patent/WO2020141470A1/en unknown
- 2020-01-02 CN CN202080007931.8A patent/CN113302188A/zh active Pending
- 2020-01-02 SG SG11202106897XA patent/SG11202106897XA/en unknown
- 2020-01-02 AU AU2020205035A patent/AU2020205035A1/en not_active Abandoned
- 2020-01-02 EP EP20701499.4A patent/EP3906234A1/en not_active Withdrawn
-
2021
- 2021-06-29 CO CONC2021/0008535A patent/CO2021008535A2/es unknown
- 2021-07-01 IL IL284570A patent/IL284570A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022515880A (ja) | 2022-02-22 |
| MA54656A (fr) | 2022-04-06 |
| US20200216416A1 (en) | 2020-07-09 |
| SG11202106897XA (en) | 2021-07-29 |
| CN113302188A (zh) | 2021-08-24 |
| CR20210364A (es) | 2021-08-18 |
| TW202039465A (zh) | 2020-11-01 |
| CO2021008535A2 (es) | 2021-07-19 |
| TWI745824B (zh) | 2021-11-11 |
| BR112021012956A2 (pt) | 2021-10-26 |
| KR20210110664A (ko) | 2021-09-08 |
| CA3125559A1 (en) | 2020-07-09 |
| IL284570A (en) | 2021-08-31 |
| WO2020141470A1 (en) | 2020-07-09 |
| EP3906234A1 (en) | 2021-11-10 |
| UY38536A (es) | 2020-08-31 |
| AU2020205035A1 (en) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401541B1 (ar) | [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات | |
| CR20210098A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| PH12018502355A1 (en) | Enzyme inhibitors | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| SG10201907819WA (en) | N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors, | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| JOP20220142A1 (ar) | مثبطات kras g12c | |
| MX2018010192A (es) | Inhibidores de glucosidasa. | |
| PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
| MX2018010191A (es) | Inhibidores de glucosidasa. | |
| PH12015502549B1 (en) | Heterocyclic derivatives | |
| MX2021008136A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met. | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| MX2022002069A (es) | Inhibidores de enzimas. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2021012499A (es) | Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos. | |
| EA202190393A1 (ru) | СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TAM- И Met-КИНАЗ | |
| WO2021130700A8 (en) | Compound for the treatment of the hemolytic-uremic syndrome | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2020008273A (es) | Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos. | |
| EA201990939A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |